Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04505423 · ClinicalTrials.gov registry record
Evaluation of Outcomes Related to Cerebrospinal Fluid Drain Placement
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 302
- Enrollment target
NCT04505423: Completed study, sponsored by University of North Carolina, Chapel Hill.
NCT04505423 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 302 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04505423 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 302 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the rate and severity of complications associated with CSFD placement either with or without fluoroscopic guidance.
Primary Outcome
The rate and severity of complications associated with CSFD placement with or without fluoroscopic guidance via a chart review. This will be assessed using quantitative methods such as vital signs and lab-work drawn relating to the procedure as well as qualitative variables through clinical notes.
Interventions
- PROCEDURE Blind CSF Drain Placement
- PROCEDURE Fluoroscopy-guided Drain Placement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2020-08-03 |
| Est. Completion | 2021-05-01 |
What the finished NCT04505423 record still lists
NCT04505423 is an observational study that tracks outcomes without assigning an intervention. The registered 302 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Blind CSF Drain Placement is the first listed.
NCT04505423 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04505423 about?
NCT04505423 is a clinical study titled "Evaluation of Outcomes Related to Cerebrospinal Fluid Drain Placement". The purpose of this study is to compare the rate and severity of complications associated with CSFD placement either with or without fluoroscopic guidance.
What is the current status of trial NCT04505423?
This trial is currently completed. The enrollment target is 302 participants. The study started on 2020-08-03. Estimated completion is 2021-05-01.
What interventions are being tested in trial NCT04505423?
The interventions under investigation include: Blind CSF Drain Placement (PROCEDURE), Fluoroscopy-guided Drain Placement (PROCEDURE).
Who is sponsoring clinical trial NCT04505423?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05722561 · 302 participants · Phase 2
E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
- NCT06015737 · 302 participants · Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
- NCT07176273 · 302 participants · NA
Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)
- NCT05508971 · 303 participants · NA
Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Down Syndrome (TOPS-DS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI